Diaz-Arias A A, Loy T S, Bickel J T, Chapman R K
Department of Pathology, University of Missouri Medical School, Columbia.
Diagn Cytopathol. 1993 Oct;9(5):516-21. doi: 10.1002/dc.2840090509.
The usefulness of a new commercially available monoclonal antibody (MoAb) BER-EP4 was evaluated. This MoAb is directed against a cell surface glycoprotein reported to be present in most epithelial cells and epithelial tumors but not in mesothelial cells. Cell block sections from 103 adenocarcinomatous and 129 benign effusions were studied. Positive staining was seen in 85 of the 103 (83%) malignant effusions. Immunoreactivity was seen in 73-93% of adenocarcinomas from the ovary, gastrointestinal tract, lung, and breast. Mesothelial cells from 3 of the 129 (2%) benign effusions showed positive staining. It is concluded that immunocytochemical staining with MoAb BER-EP4 is a sensitive and specific aid in distinguishing reactive mesothelial cells from adenocarcinoma cells in body fluids.
对一种新的市售单克隆抗体（MoAb）BER-EP4的效用进行了评估。这种单克隆抗体针对一种据报道存在于大多数上皮细胞和上皮性肿瘤中但不存在于间皮细胞中的细胞表面糖蛋白。研究了来自103例腺癌性积液和129例良性积液的细胞块切片。在103例恶性积液中有85例（83%）可见阳性染色。卵巢、胃肠道、肺和乳腺的腺癌中有73%-93%可见免疫反应性。129例良性积液中有3例（2%）的间皮细胞显示阳性染色。结论是，用单克隆抗体BER-EP4进行免疫细胞化学染色是一种在体液中区分反应性间皮细胞和腺癌细胞的敏感且特异的辅助方法。
